ePrivacy and GPDR Cookie Consent by Cookie Consent

PROSTATE CANCER: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers


Nov. 18, 2019


European Urology - December 2019 Volume 76, Issue 6, Pages 831–842

An observational study confirms the increased risk of prostate cancer for carriers of pathogenic germline BRCA2 mutations and recommends PSA-based screening. The role of BRCA1 in this disease remains to be determined.


Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.


After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers.